Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 152

Sort by

Sort Order Select

Journal Articles

A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Jan A. Burger, Ekaterina Kim, Gitanjali Jayachandran, Wanda Lopez, Ghayas C. Issa, Musa Yilmaz, Mahesh Swaminathan, Jo Ishizawa, Alexandre Bazinet, Yesid Alvarado Valero, Nitin Jain, William G. Wierda, Alessandra Ferrajoli

Blood (2024) 144 (Supplement 1): 1868.

https://doi.org/10.1182/blood-2024-200331

Published: 2024

Journal Articles

Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML

Julie Braish, Guillermo Montalban-Bravo, Farhad Ravandi, Nicholas J. Short, Tapan M. Kadia, Maro Ohanian, Kelly S. Chien, Lucia Masarova, Koji Sasaki, Musa Yilmaz, Naval Daver, Gautam Borthakur, Hagop M. Kantarjian, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 3209.

https://doi.org/10.1182/blood-2024-208536

Published: 2024

Journal Articles

Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax

Jennifer Marvin-Peek, Courtney D. DiNardo, Wei-Ying Jen, Nicholas J. Short, Yesid Alvarado Valero, Gautam Borthakur, Naval Daver, Eitan Kugler, Alexandre Bazinet, Hussein A. Abbas, Musa Yilmaz, Guillermo Garcia-Manero, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 1472.

https://doi.org/10.1182/blood-2024-202405

Published: 2024

Journal Articles

Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia

Daniel Nguyen, Hagop Kantarjian, Nicholas J. Short, Nitin Jain, Fadi G. Haddad, Musa Yilmaz, Alessandra Ferrajoli, Tapan M. Kadia, Yesid Alvarado Valero, Abhishek Maiti, Marianne Zoghbi, Jayastu Senapati, Rebecca Garris, Min Zhao, Marina Konopleva, Farhad Ravandi, Elias Jabbour

Blood (2024) 144 (Supplement 1): 1439.

https://doi.org/10.1182/blood-2024-208854

Published: 2024

Journal Articles

Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3 -Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor

Nicholas J. Short, Sanam Loghavi, Musa Yilmaz, Omer Karrar, Joseph E. Jabbour, Courtney D. DiNardo, Tapan M. Kadia, Gautam Borthakur, Ghayas C. Issa, Hussein A. Abbas, Marina Konopleva, Farhad Ravandi, Hagop M. Kantarjian, Naval Daver

Blood (2024) 144 (Supplement 1): 220.

https://doi.org/10.1182/blood-2024-210891

Published: 2024

Journal Articles

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Blood (2024) 144 (Supplement 1): 216.

https://doi.org/10.1182/blood-2024-204375

Published: 2024

Journal Articles

Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH -Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials

Blood (2024) 144 (Supplement 1): 2883.

https://doi.org/10.1182/blood-2024-200387

Published: 2024

Journal Articles

A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia

Hannah Goulart, Hagop M. Kantarjian, Naval Daver, Musa Yilmaz, Guillermo Garcia-Manero, Kelly S. Chien, Jan A. Burger, Naveen Pemmaraju, Courtney D. DiNardo, Nicholas J. Short, Guillermo Montalban-Bravo, Abhishek Maiti, Danielle Hammond, Ghayas C. Issa, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 2901.

https://doi.org/10.1182/blood-2024-205340

Published: 2024

Journal Articles

Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy

Blood (2024) 144 (Supplement 1): 2896.

https://doi.org/10.1182/blood-2024-198541

Published: 2024

Journal Articles

Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy

Blood (2024) 144 (Supplement 1): 4306.

https://doi.org/10.1182/blood-2024-208602

Published: 2024

Journal Articles

Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission

Blood (2024) 144 (Supplement 1): 4277.

https://doi.org/10.1182/blood-2024-198928

Published: 2024

Journal Articles

Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up

Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Akhil Jain, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Fadi G. Haddad, Naveen Pemmaraju, Nicholas J. Short, Maro Ohanian, Musa Yilmaz, Keyur P. Patel, Mark Brandt, Sherry Pierce, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur

Blood (2024) 144 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2024-211599

Published: 2024

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2024) 144 (Supplement 1): 4263.

https://doi.org/10.1182/blood-2024-204296

Published: 2024

Journal Articles

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood (2024) 144 (Supplement 1): 1855.

https://doi.org/10.1182/blood-2024-211110

Published: 2024

Journal Articles

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2024-211454

Published: 2024

Journal Articles

Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Blood (2024) 144 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2024-208684

Published: 2024

Journal Articles

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blood (2024) 144 (Supplement 1): 446.

https://doi.org/10.1182/blood-2024-203938

Published: 2024

Journal Articles

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2024-206801

Published: 2024

Journal Articles

Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation

Courtney D. DiNardo, Kelly S. Chien, Jillian Mullin, Danielle Hammond, Jeremy Ramdial, Tapan M. Kadia, Fadi G. Haddad, Musa Yilmaz, Koji Sasaki, Ghayas C. Issa, Koichi Takahashi, Elizabeth J. Shpall, Farhad Ravandi, Naval Daver, Hagop Kantarjian

Blood (2024) 144 (Supplement 1): 1527.2.

https://doi.org/10.1182/blood-2024-208771

Published: 2024

Journal Articles

A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Trial in Progress

Nicholas J. Short, Farhad Ravandi, Naval Daver, Courtney D. DiNardo, Gautam Borthakur, Tapan M. Kadia, Musa Yilmaz, Ghayas C. Issa, Regina Abramova, Araceli Isabella Garza, Hagop M. Kantarjian, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 4288.1.

https://doi.org/10.1182/blood-2024-200923

Published: 2024

NARROW

A Phase II Study of Time-Limited Treatment with Acalabrutinib Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

Phase I/II Combination Study of Azacitidine and Venetoclax Post Hypomethylating Agents Failure in High Risk MDS and CMML

Less May be More: The Impact of Post-Remission Intensive (IC) Consolidation Cycles on Outcomes in Newly Diagnosed Acute Myeloid Leukemia Receiving IC + Venetoclax

Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia

Long-Term Survival Outcomes and Cytogenetic/Molecular Patterns of Relapse in Adults with FLT3 -Mutated AML Receiving Frontline Triplet Therapy with a Hypomethylating Agent, Venetoclax and FLT3 Inhibitor

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH -Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials

A Phase II Study of Cladribine, Idarubicin, and Cytarabine (CLIA) in Combination with Gilteritinib for Patients with Newly Diagnosed FLT3 -Mutated Acute Myeloid Leukemia

Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy

Cohesin Complex Gene Mutated Acute Myeloid Leukemia (AML) Responds Favorably to Venetoclax Based Frontline Therapy

Personalized Oral Maintenance Therapy with Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) in Acute Myeloid Leukemia in First Remission

Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation

A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Trial in Progress

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only